AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27418249
Drug: Continuous occlusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous occlusion therapy using traditional adhesive patches, 2 hours per day (occluded 100% of wear time)
Trial: 15930204
Drug: Immediate antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antibiotics (ABX; amoxicillin plus symptom medication)
Trial: 15930204
Drug: Watchful waiting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watchful waiting (WW; symptom medication only)
Trial: 15930204
Drug: Immediate antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antibiotics (ABX)
Trial: 10227568
Drug: Acarbose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (50 mg t.d.s. for the first 2 weeks, then 100 mg t.d.s. for the subsequent weeks)
Trial: 1859010
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15 micrograms/kg
Trial: 1859010
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of fentanyl citrate (control) 15 micrograms/kg
Trial: 1859010
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of fentanyl citrate (control)
Trial: 7341285
Drug: Mianserin 20
RxNorm normalized name: mianserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 20 mg tid for 3 days
Trial: 7341285
Drug: Mianserin pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin pre-treatment
Trial: 28865493
Drug: Infliximab 3
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 3 mg/kg from weeks 0 to 6, then 3, 6, or 10 mg/kg every 8 weeks from weeks 14 to 46
Trial: 25111437
Drug: Cryolipolysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryolipolysis treatment on larger thigh
Trial: 17173586
Drug: Patients in
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in group A who underwent treatment
Trial: 10715982
Drug: Perfix plug-and-patch
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfix plug-and-patch
Trial: 2995279
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g dietary fibre supplements in the form of a corn‐based biscuit (Group A)
Trial: 2995279
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g dietary fibre supplements as wheat bran (Group B)
Trial: 19673652
Drug: Cell culture-derived
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell culture-derived influenza vaccine (CCIV)
Trial: 12752139
Drug: Alefacept therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept therapy
Trial: 9350389
Drug: Slow-release lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release lithium carbonate, 800 mg/day
Trial: 1332985
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate and oestradiol valerate (PC/EV) administered until the twelfth week of gestation
Trial: 3715407
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 50 to 3900 mg daily for 1 week
Trial: 3715407
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 100 mg daily for 1 week
Trial: 3715407
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) higher doses (above 100 mg)
Trial: 16540864
Drug: Matched treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched treatment (manipulation, stabilization exercise, or specific exercise)
Trial: 16540864
Drug: Unmatched treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmatched treatment (manipulation, stabilization exercise, or specific exercise)
Trial: 12669236
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and prolonged oral etoposide (group 1; n=58)
Trial: 12669236
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and prolonged oral etoposide (group 1; n=84)
Trial: 12669236
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and high-dose intravenous etoposide (group 2; n=84)
Trial: 24424109
Drug: Generic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic preparation of 4.2 mg fentanyl
Trial: 24424109
Drug: Durogesic patch
RxNorm normalized name: Dologesic
DrugBank: Phenyltoloxamine (DB11160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Durogesic patch of 4.2 mg fentanyl
Trial: 22964716
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of UDCA (1 g/day during 3 weeks before surgery) and RIFA (600 mg/day during 1 week before surgery)
Trial: 20026112
Drug: G-CSF deficiency
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF deficiency
Trial: 12425756
Drug: ddAT (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddAT (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2) with prophylactic granulocyte colony-stimulating factor support (5 micro g/kg days 5-10)
Trial: 30608308
Drug: Constraint‐induced movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐induced movement therapy (CI therapy)
Trial: 30608308
Drug: CI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI therapy
Trial: 23378458
Drug: Wellmune (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wellmune (250 mg daily for 12 weeks)
Trial: 23378458
Drug: Placebo (self-administered)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (self-administered)
Trial: 19765608
Drug: Boy Scout
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boy Scout Five‐A‐Day Badge program (9-week program with 30 min weekly troop time and 25 min weekly Internet programming)
Trial: 17530530
Drug: Zileuton controlled
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zileuton controlled release (CR) 1,200 mg BID
Trial: 14998852
Drug: MMC +
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC + GEM (Mitomycin C 8 mg/m2 on day 1 + Gemcitabine 2000 mg/m2 on days 1 and 15 every 4 weeks)
Trial: 14998852
Drug: MMC +
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC + CAPE (Mitomycin C 8 mg/m2 on day 1 + Capecitabine 2000 mg/m2/day on days 1-14 every 4 weeks)
Trial: 11514369
Drug: Intravenous gamma
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gamma globulin therapy
Trial: 9700472
Drug: Alendronate 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 2.5 mg/day (L)
Trial: 9700472
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg/day (H)
Trial: 8077368
Drug: beta-endorphin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-endorphin (0.5 mg/h)
Trial: 8077368
Drug: naloxone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone (5 mg in 5 min)
Trial: 30773731
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg three times a day orally for 2 weeks
Trial: 30451560
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support group intervention (8 weekly sessions of 1.5 hours each)
Trial: 16772442
Drug: Dual fortified
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual fortified salt (DFS) with 3 mg Fe/g salt as ground FePP
Trial: 11520368
Drug: Weekly regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly regimen (paclitaxel 60 mg/m2, carboplatin AUC 2)
Trial: 11520368
Drug: Monthly regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly regimen (paclitaxel 175 mg/m2, carboplatin AUC 6)
Trial: 11520368
Drug: Weekly regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly regimen
Trial: 9777130
Drug: Reteplase administration
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reteplase administration
Trial: 9777130
Drug: Double bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double bolus alteplase administration
Trial: 7890014
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg bd)
Trial: 7890014
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 IU daily)
Trial: 27230863
Drug: 12-week Internet
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week Internet intervention (Deprexis) adjunctive to usual care
Trial: 23189301
Drug: Submerged dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submerged dental implants in organ transplant patients
Trial: 23189301
Drug: Submerged dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submerged dental implants in control patients
Trial: 10931390
Drug: G-CSF treatment
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF treatment combined with HAART
Trial: 2942599
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms of HB‐VAX vaccine
Trial: 2942599
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms of HB‐VAX vaccine
Trial: 31705154
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) under current local resources
Trial: 31705154
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) under assumed ideal conditions
Trial: 29555019
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with precise treatment expectations
Trial: 23771450
Drug: Adherence counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence counseling and twice weekly short message reminders for four months
Trial: 11034942
Drug: BQ‐123 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ‐123 (6 micromol/L over 20 minutes)
Trial: 18349194
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of liquid sevoflurane to achieve a target end-tidal concentration of 1%
Trial: 18349194
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of liquid sevoflurane to achieve a target end-tidal concentration of 1.5%
Trial: 18349194
Drug: Infusion scheme
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion scheme to increase target concentration by 0.3%
Trial: 18349194
Drug: Infusion scheme
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion scheme to decrease target concentration by 0.3%
Trial: 14640465
Drug: Simvastatin (20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20-80 mg)
Trial: 9413107
Drug: Two primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two primary doses of DTaP
Trial: 9413107
Drug: Three primary
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three primary doses of DTaP
Trial: 9413107
Drug: Two primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two primary doses of DTaP followed by a booster
Trial: 9413107
Drug: Three primary
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three primary doses of DTaP followed by a booster
Trial: 3758146
Drug: DHE 1
RxNorm normalized name: Dihydroergotamine
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DHE 1 mg intranasally
Trial: 3758146
Drug: DHE 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHE 0.5 mg intramuscularly
Trial: 21256606
Drug: Adenosine 50
RxNorm normalized name: adenosine 50 mcg/mL-NaCl 0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine 50 μg (n=54)
Trial: 21256606
Drug: Nicorandil 4
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 4 mg (n=54)
Trial: 21256606
Drug: Adenosine-nicorandil combination
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine-nicorandil combination (n=50)
Trial: 14531555
Drug: 5-aminolevulinic acid
RxNorm normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminolevulinic acid (5-ALA) administration for fluorescence-guided resections
Trial: 8613538
Drug: DHA-rich oil
RxNorm normalized name: Ulkenia DHA oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich oil capsules (1.5-1.8 grams DHA/day)
Trial: 10419086
Drug: Control oil
RxNorm normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control oil capsules (97% soybean oil + 3% fish oil)
Trial: 3882681
Drug: Fluoxetine 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 75 mg
Trial: 29368635
Drug: Strict glycaemic
RxNorm normalized name: Euphrasia stricta extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict glycaemic control (4-7 mmol/L; 72-126 mg/dl)
Trial: 29368635
Drug: Conventional glycaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycaemic control (<10 mmol/L; 180 mg/dl)
Trial: 18413554
Drug: Simvastatin, 20
RxNorm normalized name: Simvastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 20 mg
Trial: 10601051
Drug: Intraduodenal long
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal long chain triglyceride (LCT) infusion
Trial: 10601051
Drug: Intraduodenal medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal medium chain triglyceride (MCT) infusion
Trial: 3516395
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (3 g/m2 every 12 hours for 6 days)
Trial: 3516395
Drug: Amsacrine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amsacrine (75 mg/m2 daily for 7 days)
Trial: 23567070
Drug: Paricalcitol treatment
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol treatment
Trial: 16887443
Drug: Prednisone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1 mg/kg/day for 2 weeks, with weaning over the subsequent 2 weeks)
Trial: 9024171
Drug: Acetaminophen coadministered
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen coadministered with isoniazid (8 am dose)
Trial: 9024171
Drug: Acetaminophen given
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen given 12 hours after isoniazid dose
Trial: 9024171
Drug: Acetaminophen with
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with isoniazid for fast acetylators
Trial: 9024171
Drug: Acetaminophen with
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with isoniazid for slow acetylators
Trial: 8155010
Drug: Aspirin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (30 or 283 mg/d)
Trial: 30282670
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg/week for 24 weeks, then 25 mg/week)
Trial: 18196524
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin (SV) tablet formulation
Trial: 17075122
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m2 plus docetaxel 75 mg/m2 (arm B)
Trial: 8612412
Drug: Propofol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.75 mg/kg)
Trial: 8612412
Drug: Propofol (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.35 mg/kg)
Trial: 1329937
Drug: Variable oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable oestrogen dosage regimen
Trial: 1329937
Drug: Fixed 1
RxNorm normalized name: cariprazine
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed 1 mg oestrogen dosage regimen
Trial: 1329937
Drug: Fixed 2
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed 2 mg oestrogen dosage regimen
Trial: 1329937
Drug: Fixed 4
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed 4 mg oestrogen dosage regimen
Trial: 6574611
Drug: Fortnightly sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortnightly sodium fluoride rinsing and topical painting with ferric aluminum fluoride solution
Trial: 6574611
Drug: Fortnightly sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortnightly sodium fluoride rinsing and topical painting with neutral 0.2% sodium fluoride solution
Trial: 19249429
Drug: clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD)
Trial: 19249429
Drug: prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prasugrel 60 mg LD/10 mg MD
Trial: 15097437
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (0.3 g/kg/day for 7 days)
Trial: 9489975
Drug: Urokinase (192
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase (192 U/ml, 1920 U/ml, 19,200 U/ml)
Trial: 9489975
Drug: Tissue-type plasminogen
RxNorm normalized name: Tissue-type plasminogen activator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-type plasminogen activator (120 U/ml, 1200 U/ml, 12,000 U/ml)
Trial: 9489975
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (160 mg/day)
Trial: 9489975
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (660 mg/day)
Trial: 7838915
Drug: d-amphetamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (15 mg) with vigilance activity
Trial: 7838915
Drug: triazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triazolam (0.25 mg) with relaxation activity
Trial: 7838915
Drug: d-amphetamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (15 mg) with relaxation activity
Trial: 7838915
Drug: triazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triazolam (0.25 mg) with vigilance activity
Trial: 3169214
Drug: Budesonide (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (high dose, 1,000 and 1,200 micrograms per day)
Trial: 3169214
Drug: Beclomethasone (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone (high dose, 1,000 and 1,200 micrograms per day)
Trial: 12207833
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplement
Trial: 30762945
Drug: Noradrenaline infusion
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline infusion (median dose after 50 min 0.09 (range 0-0.26) μg kg-1 min-1)
Trial: 30762945
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard care, NA administered only if MAP decreased below 60 mmHg)
Trial: 23600548
Drug: 300IR 5-grass
RxNorm normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300IR 5-grass pollen sublingual tablet